Clinical trial · Observational
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence
NCT02486640CI-TRIAL-00068201BETAPREDICTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Sclerosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Betaconnect Autoinjector | Device | — | UNRESOLVED |
| Interferon beta-1b (Betaferon, BAY86-5046) | Drug | Interferon Beta-1b | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Betaferon
- interventionNames
- Drug: Interferon beta-1b (Betaferon, BAY86-5046)
- Device: Betaconnect Autoinjector
Primary outcomes (3)
- measure
- Compliance to therapy (%)
- timeFrame
- 12 months
- description
- Compliance (%) = ((expected # of treatment days during observation period - missed # of treatment days during observation period)/(expected # of treatment days during observation period))\*100
- measure
- Persistence of therapy (Yes or No)
- timeFrame
- 12 months
- description
- Persistence is defined as patients continuing ("persisting") their medication (regardless of the frequency of intake)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome * Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician * Patients using or willing to use the BETACONNECT autoinjector for Betaferon application * Written informed consent Exclusion Criteria: * Patients receiving any other disease modifying drug * Contraindications of Betaferon described in the Summary of Product Characteristics * Patients participating in any other clinical or non-interventional study, evaluating MS therapy
References
Publications (1)
- DERIVEDKohler W, Bayer-Gersmann K, Neusser T, Schurks M, Ziemssen T. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT(R) Autoinjector: A Prospective Observational Cohort Study. Front Neurol. 2021 Feb 24;12:643126. doi: 10.3389/fneur.2021.643126. eCollection 2021. PMID 33716945